310 related articles for article (PubMed ID: 28885734)
21. Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.
Zhang J; Ranheim EA; Du J; Liu Y; Wang J; Kong G; Zhang J
J Biol Chem; 2015 Jul; 290(31):19093-103. PubMed ID: 26082490
[TBL] [Abstract][Full Text] [Related]
22. Specific skin infiltration as first sign of chronic myelomonocytic leukemia with an unusual phenotype.
Braga D; Manganoni AM; Boccaletti V; Pancera C; Marocolo D; Facchetti F; De Panfilis G
J Am Acad Dermatol; 1996 Nov; 35(5 Pt 2):804-7. PubMed ID: 8912590
[TBL] [Abstract][Full Text] [Related]
23. Leukemia cutis masquerading as vitiligo.
Newman MD; Milgraum S
Cutis; 2008 Feb; 81(2):163-5. PubMed ID: 18441770
[TBL] [Abstract][Full Text] [Related]
24. [Neoplastic skin infiltration in chronic myelomonocytic leukemia].
Wajs J; Zabielski S; Trawiński J
Pol Merkur Lekarski; 2001 Nov; 11(65):427-9. PubMed ID: 11852815
[TBL] [Abstract][Full Text] [Related]
25. Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.
Bernard V; Gebauer N; Dinh T; Stegemann J; Feller AC; Merz H
Int J Clin Exp Pathol; 2014; 7(4):1667-76. PubMed ID: 24817963
[TBL] [Abstract][Full Text] [Related]
26. The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice.
Ritchie KA; Aprikyan AA; Bowen-Pope DF; Norby-Slycord CJ; Conyers S; Bartelmez S; Sitnicka EH; Hickstein DD
Leukemia; 1999 Nov; 13(11):1790-803. PubMed ID: 10557054
[TBL] [Abstract][Full Text] [Related]
27. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous Langerhans cell histiocytosis in elderly with chronic myelomonocytic leukemia.
Iwasaki T; Takahashi I; Nagashima T; Igawa S; Komatsu S; Honma M; Ishida-Yamamoto A; Iizuka H
J Dermatol; 2014 Mar; 41(3):262-5. PubMed ID: 24628074
[TBL] [Abstract][Full Text] [Related]
29. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
[TBL] [Abstract][Full Text] [Related]
30. Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia.
Sun Q; So CC; Yip SF; Wan TS; Ma SK; Chan LC
Leuk Res; 2008 Sep; 32(9):1374-81. PubMed ID: 18372040
[TBL] [Abstract][Full Text] [Related]
31. Age-related mutations and chronic myelomonocytic leukemia.
Mason CC; Khorashad JS; Tantravahi SK; Kelley TW; Zabriskie MS; Yan D; Pomicter AD; Reynolds KR; Eiring AM; Kronenberg Z; Sherman RL; Tyner JW; Dalley BK; Dao KH; Yandell M; Druker BJ; Gotlib J; O'Hare T; Deininger MW
Leukemia; 2016 Apr; 30(4):906-13. PubMed ID: 26648538
[TBL] [Abstract][Full Text] [Related]
32. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
[TBL] [Abstract][Full Text] [Related]
33. [Clinical course, morphology and prognosis of chronic myelomonocytic leukemia].
Germing U; Strupp C; Meckenstock G; Giagounidis A; Minning H; Aul C
Med Klin (Munich); 1999 Sep; 94(9):467-72. PubMed ID: 10544608
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.
Bacher U; Haferlach T; Schnittger S; Kreipe H; Kröger N
Br J Haematol; 2011 Apr; 153(2):149-67. PubMed ID: 21401573
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow trephine morphology and immunohistochemical findings in chronic myelomonocytic leukaemia.
Ngo NT; Lampert IA; Naresh KN
Br J Haematol; 2008 Jun; 141(6):771-81. PubMed ID: 18371110
[TBL] [Abstract][Full Text] [Related]
36. Blastic Transformation in Mexican Population With Chronic Myelomonocytic Leukemia.
Rivera Duarte A; Armengol Alonso A; Sandoval Cartagena E; Tuna Aguilar E
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):532-538. PubMed ID: 28842140
[TBL] [Abstract][Full Text] [Related]
37. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
[TBL] [Abstract][Full Text] [Related]
38. Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms.
Patnaik MM; Lasho T; Howard M; Finke C; Ketterling RL; Al-Kali A; Pardanani A; Droin N; Gangat N; Tefferi A; Solary E
Blood Cancer J; 2018 Aug; 8(9):82. PubMed ID: 30190511
[No Abstract] [Full Text] [Related]
39. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
Harada Y; Harada H
Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
[TBL] [Abstract][Full Text] [Related]
40. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2012 Jun; 87(6):610-9. PubMed ID: 22615103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
